AtaGenix Laboratories
AtaGenix Laboratories
AtaGenix provides bispecific antibody (BsAb) development services covering format design, gene construction, expression, purification, and QC — from antibody sequences to purified bispecific material in as fast as 5 weeks. Our team has hands-on experience across both IgG-like formats (Knobs-into-holes, CrossMab, Ortho-Fab, IgG-scFv) and non-Fc formats (BiTE, tandem scFv, DART, TandAbs, bi-Nanobody).
~5 wks
Sequence to Purified BsAb
9+
BsAb Formats Supported
CHO/HEK
Expression Systems
Full QC
SDS-PAGE + Report
Bispecific antibodies engage two different targets simultaneously — enabling T-cell redirection, dual pathway blockade, and bispecific ADC strategies. The engineering challenge is ensuring correct heavy/light chain pairing and heterodimer formation. AtaGenix addresses this through format-specific design strategies including Knobs-into-holes CH3 mutations, CrossMab domain exchange, and electrostatic steering.
| Category | Format | Key Feature |
| IgG-like (with Fc) | Knobs-into-holes (KIH) | CH3 mutations promote heavy chain heterodimerization (>92% correct pairing) |
| CrossMab | CL/CH1 domain exchange prevents light chain mispairing; built on KIH backbone | |
| Ortho-Fab | Orthogonal VH/VL + CH1/CL mutations minimize light chain mismatch | |
| IgG-scFv / scFv2-Fc | scFv fused to IgG C-terminus or Fc; retains ADCC/CDC effector function | |
| Non-Fc (fragments) | BiTE | Anti-CD3 scFv + anti-tumor scFv; T-cell redirecting; proven clinical format |
| Tandem scFv | Two scFvs linked by flexible peptide; small size, good tissue penetration | |
| DART / TandAbs | Diabody-based; forced heterodimerization through interchain disulfide | |
| bi-Nanobody | Two VHH domains linked; smallest bispecific (~30 kDa); easy to express in E. coli |
Format-Specific Engineering
Not a one-size-fits-all approach. We select the optimal format based on your targets, desired mechanism (T-cell redirect, dual blockade, ADC), and developability requirements. KIH/CrossMab for IgG-like PK; BiTE/tandem scFv for tissue penetration.
5-Week Turnaround
From your antibody sequences to purified bispecific protein in approximately 5 weeks. Includes gene synthesis, codon optimization, vector construction, CHO or HEK expression, purification, and QC analysis.
Proven Format Portfolio
Hands-on experience with 9+ bispecific formats including the most clinically advanced architectures (KIH, CrossMab, BiTE). Case examples include successful Tandem scFv and CrossMab productions with confirmed SDS-PAGE QC.
AtaGenix's bispecific antibody service takes your antibody sequences through gene synthesis, codon optimization, vector construction, CHO or HEK expression, purification, and QC analysis — delivering purified bispecific antibody with a detailed technical report in approximately 5 weeks. We support both IgG-like formats (Knobs-into-holes, CrossMab, Ortho-Fab, IgG-scFv, scFv2-Fc) and non-Fc formats (BiTE, tandem scFv, DART, TandAbs, bi-Nanobody). Fc engineering for effector function modulation is available upon request.
A streamlined 4-stage pipeline from your antibody sequences to purified bispecific material. Total timeline: ~5 weeks.
01
Gene & Vector
Codon optimization
Gene synthesis
BsAb vector construction
(KIH/CrossMab/BiTE/etc.)
02
Expression
CHO or HEK transient
HC/LC ratio optimization
Heterodimer formation
03
Purification
Protein A/G capture
Polishing chromatography
Heterodimer enrichment
04
QC & Delivery
SDS-PAGE (R + NR)
Purity & identity confirmation
Technical report
Service Scope
| ✓ Gene synthesis & codon optimization | ✓ BsAb-specific vector construction |
| ✓ KIH / CrossMab / Ortho-Fab / BiTE / tandem scFv | ✓ CHO or HEK transient expression |
| ✓ HC/LC ratio optimization for correct pairing | ✓ Protein A/G + polishing purification |
| ✓ SDS-PAGE QC (reducing + non-reducing) | ✓ Optional: SEC-HPLC, SPR/Biacore, cell-based assay |
| ✓ Fc engineering available (effector function modulation) | ✓ Purified BsAb + detailed technical report |
| Factor | IgG-like (KIH, CrossMab) | Non-Fc (BiTE, tandem scFv) |
| Size | ~150 kDa (full IgG) | ~55–100 kDa |
| Half-life | Long (FcRn recycling, weeks) | Short (hours; may need half-life extension) |
| Effector Function | ADCC / CDC via Fc (tunable) | No Fc effector; T-cell redirect only |
| Tissue Penetration | Standard IgG distribution | Better (smaller size) |
| Expression Host | CHO / HEK (mammalian required) | CHO / HEK or E. coli (for bi-Nanobody) |
| Best For | Dual blockade, long-acting therapeutics | T-cell redirection, solid tumor access |
Need upstream antibody discovery first? Find your two parental antibodies via Phage Display, Rapid Hybridoma, or Rabbit Single B Cell, then feed sequences directly into our BsAb engineering pipeline.
Which bispecific format should I choose?
It depends on your mechanism and development stage. IgG-like formats (KIH, CrossMab) are preferred when you need Fc-mediated effector function (ADCC/CDC) and long serum half-life. Non-Fc formats (BiTE, tandem scFv) are better for T-cell redirection where fast clearance is acceptable and smaller size improves tissue penetration. For nanobody-based programs, bi-Nanobody is the simplest format and can be expressed in E. coli. Our team will recommend the optimal architecture based on your target pair and intended application.
How do you ensure correct heavy chain pairing?
For Knobs-into-holes formats, we introduce asymmetric CH3 mutations (T366W "knob" + T366S/L368A/Y407V "hole") that promote heterodimer formation to >92% correct pairing. CrossMab adds CL/CH1 domain exchange to prevent light chain mispairing. Ortho-Fab uses orthogonal VH/VL mutations. Each format has a validated design template; we select the appropriate strategy based on your parental antibodies.
How long does the project take?
Approximately 5 weeks from receiving your antibody sequences to delivering purified bispecific protein with QC data. This includes gene synthesis and codon optimization, vector construction with format-specific engineering, CHO or HEK transient expression, purification, and QC analysis. Timeline may extend for complex formats or if antibody discovery is needed upstream.
What do I need to provide?
Your two parental antibody sequences (heavy chain and light chain for each arm). If you have a preferred bispecific format, let us know; otherwise our team will recommend the best architecture based on your target biology, mechanism, and development goals. If you do not yet have parental antibody sequences, we can discover them through our phage display, hybridoma, or single B cell platforms first.
Timeline assumes client-provided antibody sequences. Format complexity, expression host, and optional analytics may affect delivery. Optional QC add-ons: SEC-HPLC, SPR/Biacore, cell-based potency assay. Quote-based pricing.
Explore real-world yeast protein expression case studies from AtaGenix. Our Pichia pastoris and Saccharomyces cerevisiae platforms deliver high-yield recombinant proteins with proper folding and glycosylation — supporting enzyme production, diagnostic antigen development, and antibody screening applications.
A 2022 J. Immunology study identified shrimp MANF as a conserved anti-inflammatory plasma protein that suppresses ERK/NF-κB via RPTP binding in hemocytes. AtaGenix provided the three critical reagents that made this discovery possible: phage display-derived monoclonal antibodies for MANF detection, CHO-expressed recombinant MANF for functional signaling studies, and a custom sandwich ELISA that demonstrated LPS-induced MANF secretion in vivo. Cross-species experiments in human 293T cells confirmed the MANF–RPTP axis is conserved across 600 million years of evolution. DOI: 10.4049/jimmunol.2100595.
Contact Us
+86-27-6552-3339
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
